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A B S T R A C T   
Background: With the introduction of new therapeutic options, the landscape of metastatic bladder cancer (mBC) 
management is shifting. We describe current clinical practice and outcomes of mBC patients as a benchmark for 
translation of developments into clinical practice in the near future. 
Patients and methods: Nation-wide population-based cohort study including all patients diagnosed with syn-
chronous metastatic bladder cancer in the Netherlands in 2016–2017, identified through the Netherlands Cancer 
Registry (NCR). Clinical data on patient and disease characteristics, treatments and survival from the NCR were 
supplemented with specific information from electronic health records and descriptively analyzed. This study 
was part of the Prospective Bladder Cancer Infrastructure. 
Results: Synchronous metastatic bladder cancer was diagnosed in 636 patients in the Netherlands in 2016 and 
2017. 35% (221 patients) received systemic treatment, of whom 88 received multiple treatment lines. Most 
common first-line regimen was carboplatin-based chemotherapy (49%), followed by cisplatin-based chemo-
therapy (41%) and immunotherapy (8%). Factors associated with systemic treatment were: young age, <2 
comorbidities, adequate renal function and performance-status (WHO-0–1/Karnofsky-80–100), urothelial car-
cinoma and lymph node only metastases. Median overall survival was 4.4 months for the total cohort, and 12.3, 
12.9 and 11.1 months for patients treated with first-line immunotherapy, cisplatin-based and carboplatin-based 
chemotherapy, respectively. 
Conclusions: Many mBC patients received no systemic treatment or received carboplatin-based chemotherapy, 
partly because of cisplatin-ineligibility. Observed survival corresponded relatively well with rates reported from 
trials among chemotherapy-treated patients. These data can serve as a benchmark for future studies evaluating 
the application of immunotherapy outside a trial setting.   
Introduction 
Treatment for patients with metastatic bladder cancer (mBC) is pri-
marily directed at prolonging survival within a patient population with 
dismal prognosis. Cisplatin-based chemotherapy has shown to provide 
the best survival benefit, and is hence the preferred and guidelines- 
recommended treatment option [1,2]. A large proportion of patients 
however is ineligible to receive cisplatin as a result of poor performance 
status or renal function [3], often associated with relatively old age. 
Alternatively, patients may be treated with carboplatin-based chemo-
therapy. Since the FDA and EMA approvals of checkpoint inhibitors in 
2016 and 2017, immunotherapy has become another option in both 
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second-line therapy and first-line therapy among cisplatin-ineligible 
patients [4]. 
While optimal evidence-based decision-making on treatment options 
is important to obtain optimal outcomes, this process is hindered by 
several facts. Recommendations in guidelines in relation to systemic 
treatment of mBC are mainly based on randomized clinical trials. These 
trials include a selection of patients with a more favorable prognostic 
profile as compared to the general patient population seen in daily 
clinical practice[5,6], complicating the transportability of expected 
treatment effects to a broader patient population. This leaves the char-
acterization of a considerable group, including untreated patients, 
obscured. 
It is currently unknown to what extent anticipated bladder cancer 
treatment effects diverge between clinical practice patient populations 
and trial populations. Simultaneously, the shift in use of different sys-
temic treatment modalities among mBC patients calls for a recalibration 
of the patient and tumor characteristics associated with treatment 
choices and corresponding outcomes. The aim of this study was to 
describe current clinical practice and outcomes of mBC patients. This 
study should provide insight into how patient, disease and hospital 
characteristics are associated with different treatment options and to 
provide a benchmark for future translation of developments into clinical 
practice in the near future. 
Methods 
Cohort 
A cohort of patients diagnosed with synchronous metastatic bladder 
cancer in the period 2016–2017 was identified from the Netherlands 
Cancer Registry (NCR). The NCR is a nation-wide population-based 
registry, held by the Netherlands Comprehensive Cancer organisation 
(IKNL), that includes all cancer diagnoses of residents of the Netherlands 
since 1989. Patients with metachronous metastases were not included in 
the cohort because they currently cannot be identified from the NCR. 
This study is carried out as part of ProBCI (Prospective Bladder Cancer 
Infrastructure). No written informed consent from patients was required 
under the Dutch law. The study was approved by the Privacy Review 
Board of the Netherlands Cancer Registry (reference K19.163). 
Clinical data 
The NCR contains data on patient and tumor characteristics, disease 
stage and initial treatment. These data were supplemented with specific 
information retrieved from electronic health records by data managers 
of the NCR. Additionally retrieved data concerned the patient (BMI, 
comorbidities, performance status etc.), laboratory blood work, data on 
all applied treatments, and oncologic follow-up (i.e. disease progression, 
survival). Clinical data follow-up was completed until June 2019. 
For patients diagnosed in 2016 and 2017, TNM classification ver-
sions 7 and 8 were used, respectively, with no differences in definition of 
cM+ disease between these versions. Eligibility for cisplatin-based 
chemotherapy was defined as a renal function of ≥ 60 mL/min/ 
1.73m2 and an ECOG performance status of 0 or 1 [7]. If performance 
was documented as Karnofsky Performance Score, it was converted (KPS 
100 to ECOG 0, KPS 80–90 to ECOG 1, KPS 60–70 to ECOG 2, KPS 40–50 
to ECOG 3 and 10–30 to ECOG 4) [8]. 
Hospital characteristics were also considered as possible de-
terminants of treatment. Hospital type was categorized into community 
hospital, non-university referral hospital and university hospital. Non- 
university referral hospitals are hospitals that provide a wider range of 
care than community hospitals at higher volumes and additionally un-
dertake research and training, while university medical centers combine 
key tasks of patient care, training and education and research. 
The hospital of diagnosis was defined as the hospital of the first visit 
regarding the (suspicion of) bladder cancer; this is usually the hospital 
where the diagnosis was made, i.e. pathological confirmation of the 
bladder cancer. The treatment hospital was defined as the hospital 
where treatment took place. In case a patient underwent multiple 
treatments in different hospitals; the treatment hospital represents the 
hospital of first line of systemic therapy, hospital of radical cystectomy, 
hospital of radiotherapy to the bladder (excluding radiotherapeutic in-
stitutions), hospital of surgical treatment of metastasis or hospital of 
radiotherapy to metastasis, in decreasing hierarchy. In case the patient 
underwent no treatment, the treatment hospital is the same as the 
hospital of diagnosis. 
Statistical analyses 
Results of descriptive analyses were presented as frequencies and 
percentages for categorical variables and as means with standard de-
viations or median with interquartile range for continuous variables. 
Distributions of variables were compared between groups through Chi- 
square tests for categorical variables or ANOVA for continuous vari-
ables. Unadjusted progression-free survival (PFS) and overall survival 
(OS) were calculated with the Kaplan-Meier method. 
Results 
Cohort 
Synchronous metastatic bladder cancer was diagnosed in 636 pa-
tients in the Netherlands in 2016 and 2017. The majority was male 
(69%). The median age at diagnosis was 72 years (Table 1). About a 
quarter of all patients (23%) had only distant lymph node involvement; 
all other patients had other site involvement with or without distant 
lymph node involvement. 
Treatments 
Of all 636 patients, 35% (n = 221) received at least one line of sys-
temic treatment and 14% (n = 88) received two or more lines (Figs. 1 2). 
Most commonly used systemic treatment was carboplatin-based 
chemotherapy (49%; 108/221) followed by cisplatin-based chemo-
therapy (41%; 90/221) and immunotherapy (8%; 18/221) in the first- 
line. In the second line, immunotherapy (61%; 54/88) was most com-
mon. Of patients who received no systemic treatment, 49 (12%) un-
derwent palliative radiotherapy to the bladder or radical cystectomy (4; 
1%). Of patients who were treated with systemic treatment, 19 (9%) 
underwent prior treatment directed at metastases (resection or radia-
tion) and 14 (6%) patients received radiotherapy to the bladder. Eleven 
patients (5%) underwent a radical cystectomy after at least one line of 
systemic treatment; none underwent radical cystectomy prior to sys-
temic treatment. 
In 67% of systemically treated patients (145/221, adjustments to the 
first-line regimen were made, of which most took place in cisplatin and 
carboplatin-treated patients (Table 2). Cycle reductions or early termi-
nation were the most common adjustments to chemotherapy, and 
termination after progressive disease in case of immunotherapy. Most 
frequently documented reasons for adjustments were hematological 
toxicity or non-response during chemotherapy and progressive disease 
during immunotherapy. 
Factors associated with type of treatment 
Univariable analyses showed that patients undergoing first-line 
cisplatin-based chemotherapy were younger, had less comorbidities, 
and had a better renal function and performance score as compared to 
carboplatin-based chemotherapy or immunotherapy-treated patients 
(Table 3). Patients treated with immunotherapy were more often fe-
male, more often had urothelial carcinoma and lymph node only me-
tastases. Patients not undergoing any systemic treatment were older and 
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less fit (worse renal function, worse performance score), more often had 
non-urothelial carcinoma and deviating laboratory values. Time be-
tween diagnosis and start of first-line therapy was longer for immuno-
therapy than chemotherapy. 
Cisplatin eligibility based on renal function and performance status 
was higher among cisplatin-treated patients than carboplatin-treated 
patients (57% vs 32%). Of the 35 carboplatin-treated patients who 
appeared to be cisplatin-eligible based on renal function and WHO 
performance status, 17 had 2 or more comorbidities with an average age 
of 76. Of the remaining 18 patients with one or no comorbidities, the 
average age was 68. 
Use of type of fist-line systemic treatment was comparable between 
different hospital types where the patient was diagnosed (Table 4). 
Utilization of first-line treatment varied geographically; in the Northern 
part up to 24% of mBC patients received carboplatin and 4% cisplatin- 
based chemotherapy, whereas this was 10% and 16% in the Rotter-
dam region, respectively. 
Oncological outcome 
Median overall survival after diagnosis was 4.4 months for the total 
cohort. Median OS (mOS) from diagnosis (Fig. 3A) was worst in patients 
without any systemic treatment (2.5 months) and ranged from 11.1 
(carboplatin) to 12.9 (cisplatin) months among treated patients. Median 
OS since start of therapy (Fig. 3B) ranged from 5.4 (immunotherapy) to 
11.3 months (cisplatin). Median PFS (mPFS) since start of first-line 
therapy (Fig. 3C) ranged from 3.9 (immunotherapy) to 6.3 months 
(cisplatin). 
In patients previously treated with either cisplatin or carboplatin- 
based chemotherapy, mOS since start of second-line immunotherapy 
was 7.2 months among previously cisplatin-treated patients and 4.1 
months among previously other chemotherapy-treated patients 
(Fig. 3D). 
Discussion 
In this study, we describe the utilization of systemic treatment as 
well as the oncological outcome in a population-based cohort of patients 
with synchronous mBC. Among the minority of patients who received 
systemic treatment, the most common type was carboplatin-based 
chemotherapy. A major part of the study population was not deemed 
eligible for cisplatin-based chemotherapy, resulting in a large propor-
tion of patients not being systemically treated or alternatively being 
treated with carboplatin-based chemotherapy. 
Application of other than guideline-preferred treatments was asso-
ciated with the most obvious clinical features (i.e. renal function, per-
formance, comorbidities). Although patient preference will play a role in 
the decision to withhold systemic therapy altogether, it is unlikely that it 
explains why patients seemingly eligible for cisplatin were treated with 
carboplatin-based chemotherapy. Notably, at least 35 patients appeared 
cisplatin-eligible based on renal function and performance, but were 
nonetheless treated with first-line carboplatin-based chemotherapy. As 
all included patients had metastases upon first diagnosis of bladder 
cancer, they did not undergo previous chemotherapy in neoadjuvant 
setting either. The 35 seemingly cisplatin-eligible patients did not 
Table 1 
Patient and tumor characteristics at diagnosis.   
N % 
Sex   
Male 437 69% 
Female 199 31% 
Age   
Median, IQR 72 65–79 
Number of comorbidities   
0 190 30% 
1 149 23% 
2 or more 297 47% 
Body mass index   
<20 44 7% 
20–22.5 83 13% 
22.5–25 131 21% 
25–30 171 27% 
>30 75 12% 
Unknown 132 21% 
Performance status at diagnosis   
ECOG 0 92 14% 
ECOG 1 126 20% 
ECOG 2 65 10% 
ECOG 3/4 65 10% 
Unknown 288 45% 
Renal function (mL/min/1.73m2) at diagnosis   
0–30 81 13% 
30–60 226 36% 
60–90 232 36% 
90+ 53 8% 
Unknown 44 7% 
EORTC eligibility*   
No 353 56% 
Yes 131 21% 
Unknown 152 24% 
Dominant morphology   
Urothelial cell carcinoma 511 80% 
Large-cell carcinoma 6 1% 
Neuro-endocrine carcinoma 4 1% 
Small-cell carcinoma 21 3% 
Mixed small/large-cell carcinoma 16 3% 
Squamous cell carcinoma 16 3% 
Adenocarcinoma 15 2% 
Not specified/other 47 7% 
Metastases (categories not mutually exclusive)   
Liver metastases 108 17% 
Lung metastases 195 31% 
Bone metastases 143 22% 
Distant lymph node metastases 280 44% 
Other sites 109 17% 
Lymph node only metastases 148 23%  
* EORTC eligibility: cisplatin-eligible based on renal function ≥ 60 ml/min/ 
m2 and ECOG 0/1. 
Fig. 1. Lines of systemic treatment of synchronous metastatic bladder cancer 
patients among patients with at least one line of systemic therapy. 
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undergo earlier chemotherapy for other malignancies either. In about 
half of these patients, there was considerable comorbidity present 
despite sufficiently good performance, but comorbidity and age did not 
provide indications for the choice for carboplatin-based chemotherapy 
in the remaining patients. As cisplatin-based chemotherapy required a 
two-day hospital admission during the study period, this may be a 
reason that tilted patient’s preference to non-cisplatin-based chemo-
therapy. A large observational study in the U.S.A. also showed appli-
cation of cisplatin-containing regimens to be discordant with cisplatin- 
eligibility based on renal status and performance status [9]. The pro-
portions of patients undergoing second and third line systemic treat-
ments, which was 40% (88/221) and 9% (19/221), respectively, in the 
current study are also in line with or slightly higher than studies from 
the U.S.A. among mBC patients [9,10]. Proportions of patients receiving 
first-line cannot be compared as these studies only report on patients 
undergoing at least one line. 
Observed survival rates provide valuable information regarding 
translatability of results reported from trials when compared to clinical 
practice. For cisplatin-treated patients (mostly Gem-Cis regimens), sur-
vival times correspond well with the reported mPFS and mOS of the 
Gem-Cis arm of the trial comparing Gem-Cis to MVAC [11] (mPFS 7.7; 
mOS 14.0 months) and the trial comparing MVAC to ddMVAC [12] 
(mPFS 9.7; mOS 14.1 months). For the carboplatin-treated patients, 
trial-reported mPFS and mOS are lower than survival times estimated in 
the current study. For carboplatin-treated patients, De Santis et al. found 
a mPFS and mOS of 5.8 and 9.3 months among cisplatin-ineligible pa-
tients [13], and Dogliotti et al. estimated 7.7 and 9.8 months for 
cisplatin-eligible patients [14]. Within the current cohort, the total 
carboplatin-treated group had a mPFS and mOS of 7.7 and 11.1 months 
(7.7 and 11.6 months for the cisplatin-ineligible subgroup). 
The first-line immunotherapy-treated patients in this cohort were 
treated in context of a trial since immunotherapy was not approved yet. 
A comparison of overall survival between this cohort and earlier trial 
populations treated with immunotherapy is therefore not useful. How-
ever, the observed survival rates in the current and earlier studies 
emphasize that when future comparisons are made, they should take 
into account a sufficiently long follow-up time as immunotherapy may 
provide less short-term but more long-term benefit in some patients 
[15]. It is however striking that the time between diagnosis and start of 
first-line immunotherapy is considerably longer than for other systemic 
Fig. 2. Flowchart of numbers of patients per systemic treatment line.  
Table 2 









N % N % N % N % 
No. of administered cycles         
1 3 17% 15 17% 14 13% 9 17% 
2 3 17% 8 9% 11 10% 4 7% 
3 2 11% 10 11% 18 17% 8 15% 
4 – – 15 17% 14 13% 5 9% 
5 2 11% 10 11% 6 6% 3 6% 
6 – – 25 28% 37 34% 2 4% 
7 or more 1 6% 1 1% 4 4% 6 11% 
Maintenance 1 6% – – – – 5 9% 
Unknown 6 33% 5 6% 4 4% 12 22% 
Any adjustment or termination 8 44% 62 69% 74 69% 32 54% 
Type(s) of adjustment         
Dose reduction – – 21 23% 29 27% – – 
Cycle reduction – – 38 42% 48 44% – – 
Cycle postponement – – 18 20% 21 19% 3 6% 
Termination after progressive disease 8 44% – – – – 29 54% 
Reason(s) for adjustment/termination         
Hematological toxicity 2 11% 22 24% 40 37% 4 7% 
Gastrointestinal toxicity 1 6% 9 10% 6 6% 1 2% 
Neurological toxicity – – 1 1% 2 2% – – 
Other, physical 2 11% 13 14% 12 11% 9 17% 
Non-response 1 6% 22 24% 16 15% 4 7% 
Progressive disease 8 39% 13 14% 16 15% 19 35%  
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treatments. This may be a result of study procedures to be carried out or 
a delay caused by referral to a hospital participating in the trial. 
Because the survival times in this study are estimated among patients 
who survived long enough to undergo systemic treatment (unlike in trial 
settings where all randomized patients are analyzed in the randomiza-
tion arm for intention-to-treat analyses), a direct comparison may lead 
to overestimation of the observed survival estimates in the current study 
due to immortal time bias. Also, progression is more rigidly defined in a 
trial setting than in clinical practice, but this difference in definition is 
not applicable to overall survival. Lastly, the current study only in-
corporates patients with synchronous metastases, whereas most trials on 
systemic therapy for mBC include patients progressed from MIBC as well 
[16]. It should be taken into account that bladder cancer patients with 
synchronous metastases have not received any treatments yet as 
opposed to patients with metachronous metastatic disease, but other 
possible prognostic differences have not been documented. The survival 
differences between this cohort and trial patients are at least partially 
explained by different prognostic profiles among trial and clinical 
Table 3 
Factors potentially associated with first-line systemic treatment.   
None (n = 415) Immunotherapy (n = 19) Cisplatin-based chemotherapy (n =
90) 
Carboplatin-based chemotherapy (n =
108)   
N/ median %/ IQR N/ median %/ IQR N/ median %/ IQR N/ median %/ IQR P values§
Age (categories) 
<60 45 11% 5 28% 28 31% 21 19% <0.0001 
60–69 78 19% 8 44% 38 42% 28 26%  
70–79 155 37% 4 22% 24 27% 45 42%  
80+ 137 33% 1 6% – – 14 13%  
Age (continuous) 76 (67–82) 64 (57–71) 66 (57–70) 70 (63–76) 0.0054 
Sex 
Male 278 67% 10 56% 62 69% 82 76% 0.2035 
Female 137 33% 8 44% 28 31% 26 24%  
BMI          
<20 28 7% 3 17% 7 8% 6 6% 0.0060 
20–25 131 32% 4 22% 37 41% 41 38%  
>25 150 36% 9 50% 36 40% 49 45%  
Unknown 106 26% 2 11% 10 11% 12 11%  
No. of comorbidities 
0 114 27% 4 22% 39 43% 30 28% 0.0193 
1 94 23% 5 28% 25 28% 24 22%  
2 or more 207 50% 9 50% 26 29% 54 50%  
Renal function 
(mL/min/1.73m2)          
0–30 74 18% – – 1 1% 5 5% <0.0001 
30–60 144 35% 7 39% 13 14% 50 46%  
60–90 128 31% 7 39% 61 68% 44 41%  
90+ 33 8% 3 17% 12 13% 7 6%  
Unknown 36 8% 1 6% 3 3% 2 2%  
Performance status 
ECOG 0 28 7% 7 39% 32 36% 29 31% <0.0001 
ECOG 1 62 15% 7 39% 28 31% 35 32%  
ECOG 2 52 13% 1 6% 6 7% 8 7%  
ECOG 3/4 64 15% 1 6% 2 2% 3 3%  
Unknown 209 50% 2 11% 22 24% 33 31%  
Cisplatin eligibility* 
No 259 62% 7 39% 18 20% 58 54% <0.0001 
Yes 54 13% 9 50% 51 57% 35 32%  
Unknown 102 25% 2 11% 21 23% 15 14%  
Metastatic locations 
Bone 95 23% 4 22% 16 18% 28 26% 0.5943 
Liver 80 19% 1 6% 14 16% 12 11% 0.1119 
Lung 139 33% 7 39% 22 24% 26 24% 0.1131 
Lymph nodes 165 40% 10 56% 45 50% 56 52% 0.0457 
Other 79 19 2 11% 12 13% 15 14% 0.3566 
Lymph nodes only 80 19% 6 33% 31 34% 30 28% 0.0066 
Morphology 
UCC 321 77% 18 100% 78 87% 90 83% 0.0218 
Other 94 23% – – 12 13% 18 17%   
Value Miss% Value Miss% Value Miss% Value Miss%  
Laboratory (ref.**) 
Hb (7.5–11.0) 6.9 (6.0–7.8) 10 8.1 (6.8–8.4) 11 8.1 (7.2–8.8) 6 7.7 (6.9–8.6) 4 0.0003 
Albumin (35–55) 31 (27–37) 55 37 (35–41) 28 38 (34–42) 32 34 (30–39) 34 <0.0001 
ASAT (<40/50) 24 (17–36) 45 22 (17–36) 22 24 (19–28) 20 22 (18–29) 29 0.1498 
ALAT (<45) 18 (13–27) 43 19 (14–31) 22 20 (15–30) 19 20 (14–29) 23 0.5950 
LDH (135–225) 247 (186–350) 46 175 (144–288) 22 201 (170–242) 21 188 (173–258) 27 0.0005 
Time to start therapy 
(in days) 
- – 83 (56–101) – 41 (28–63) – 52 (37–83) – 0.0054 
Cisplatin eligibility: cisplatin-eligible based on EORTC definition of renal function ≥ 60 ml/min/m2 and ECOG 0/1. 
Miss%: percentage missing (not measured). 
* Five patients who received unknown or other type of first-line chemotherapy are excluded from this table. 
** General reference values from the Netherlands Society for Clinical Chemistry and Laboratory Medicine. 
§ P-values for continuous variables were derived from ANOVA, for categorical variables from Chi-square tests. 
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setting populations. 
Future studies could evaluate several aspects of systemic manage-
ment of metastatic bladder cancer after approval of several immuno-
therapy options. First, insight into the extend of immunotherapy 
application in different regions and hospital types would be valuable. 
Second, they could review how the distribution of patient and disease 
characteristics shifts between treatment groups after approval of 
immunotherapy for first and second lines. Moreover, they could eval-
uate whether treatment effects reported in trials are transportable to 
clinical patient populations who are receiving immunotherapy and 
identify factors associated with potential divergent treatment effects. 
This includes evaluating whether treatment onset delay for immuno-
therapy disappears outside of trial setting. 
Conclusion 
In conclusion, a large proportion of mBC patients receives no 
systemic treatment or a sub-optimal systemic treatment because of 
ineligibility for cisplatin. Although observed survival rates among 
chemotherapy-treated patients corresponded relatively well with trial- 
reported survival, this was not necessarily the case for 
immunotherapy-treated patients. This should be carefully considered 
when weighing treatment options for the entire spectrum of mBC pa-
tients, where both benefits and harms can diverge from RCT study 
populations. As treatment strategies among mBC patients continue to 
develop, including sequential application and combination of various 
systemic treatment options, it remains important to validate trial find-
ings in real-world settings. 
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Table 4 
Distribution of patients receiving different first-line systemic treatments across regions and hospital types.   
All* First-line systemic treatment*  
None Immuno-therapy Cisplatin-based chemotherapy Carboplatin-based chemotherapy  
N Col.% N Row% N Row% N Row% N Row% 
Region           
North 97 15% 66 68% 4 4% 4 4% 23 24% 
Amsterdam area 108 17% 66 61% 3 3% 17 16% 22 20% 
Middle 110 17% 70 64% 3 3% 15 14% 22 20% 
East 123 19% 76 62% 4 3% 25 20% 18 15% 
South 77 12% 54 70% 2 3% 10 13% 11 14% 
Rotterdam area 116 18% 83 72% 2 2% 19 16% 12 10% 
Diagnosis hospital           
Community hospital 268 42% 173 65% 6 2% 37 14% 52 19% 
Non-univ. referral hospital 316 50% 211 67% 11 3% 46 15% 48 15% 
University hospital 47 7% 31 66% 1 2% 7 15% 8 17%  
* Five patients who received unknown or other type of first-line chemotherapy are excluded from this table. 
Fig. 3. Progression-free and overall survival by first or second line of systemic treatment. A: Overall survival since diagnosis. B: Overall survival since start of first- 
line therapy. C: Progression-free survival since start of first-line therapy. D: Overall survival since start of second-line immunotherapy. 
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